Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Enolase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Enolase. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-006115-59 Sponsor Protocol Number: GNM-2011 Start Date*: 2012-06-11
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: "A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)"
    Medical condition: MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10018372 Glomerulonephritis membranous PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004373-40 Sponsor Protocol Number: AveNEC Start Date*: 2017-08-21
    Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz
    Full Title: A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) pr...
    Medical condition: advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006301-10 Sponsor Protocol Number: MAGNA Start Date*: 2012-05-10
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: Perioperative Magnesium Sulphate as a cerebral protector in neurosurgical patients
    Medical condition: Patient who are going to be under cerebral parenchyma resection, due to epilepsy or tumor
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10039911 Seizures (incl subtypes) HLGT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006153 Brain tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004735-39 Sponsor Protocol Number: M14NEC Start Date*: 2015-11-10
    Sponsor Name:NKI-AVL
    Full Title: Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin
    Medical condition: Patients with metastatic neuroendocrine carcinomas of extrapulmonary origin will be eligible
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002453-11 Sponsor Protocol Number: CFTSp116 Start Date*: 2018-01-19
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-li...
    Medical condition: Poorly differentiated extra-pulmonary neuroendocrine carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-004550-28 Sponsor Protocol Number: AIO-NET-0112 Start Date*: 2015-03-12
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor...
    Medical condition: • Poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC G3 according to WHO 2010) with primary tumor outside lung • Well to moderately differentiated neuroendocrine carci...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001074-26 Sponsor Protocol Number: S-CPR2011 Start Date*: 2011-11-17
    Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin
    Full Title: Effect of High Dose Selenium on Inflammation and Neurological Outcome after Cardiac Arrest: A randomized, double blind placebo controlled phase 2a study
    Medical condition: Cardiac Arrest with successful resuscitation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10007515 Cardiac arrest PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002151-10 Sponsor Protocol Number: NEUROPROTECTpost-CA Start Date*: 2015-08-07
    Sponsor Name:UZ Leuven
    Full Title: Neuroprotective goal directed hemodynamic optimization in post-cardiac arrest patients: a randomized controlled trial (the NEUROPROTECT post-CA trial)
    Medical condition: post-cardiac arrest patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10047283 Ventricular arrhythmias and cardiac arrest HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002162-40 Sponsor Protocol Number: 2021-004 Start Date*: 2022-02-21
    Sponsor Name:Haaglanden Medisch Centrum
    Full Title: IBIS: A single-centre, phase II study to evaluate the safety, tolerability and pharmacokinetics of 2-IminoBiotin in acute Ischemic Stroke due to large vessel occlusion
    Medical condition: Acute ischemic stroke due to proximal large vessel occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002887-26 Sponsor Protocol Number: CRAD001T2302 Start Date*: 2012-04-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ...
    Medical condition: Advanced neuroendocrine tumor (NET) of GI or lung origin
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) CZ (Completed) HU (Completed) ES (Completed) GB (Completed) IT (Completed) NO (Completed) NL (Completed) GR (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022679-71 Sponsor Protocol Number: Xenon-MTH-Studie Start Date*: 2011-01-07
    Sponsor Name:Clinical Trials Center Aachen, University of Aachen
    Full Title: Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation
    Medical condition: In this clinical trial will be checked, whether 2 hours ventilation with xenon has neuroprotetctive effect on the patients, which had out of hospital cardiac arrest and successful cardiopulmonary r...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10042613 - Surgical and medical procedures 10067221 Mechanical ventilation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002138-20 Sponsor Protocol Number: CURTAXEL Start Date*: 2013-10-09
    Sponsor Name:Centre Jean Perrin
    Full Title: Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resis...
    Medical condition: metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10066489 Progression of prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004429-15 Sponsor Protocol Number: GEM-1402 Start Date*: 2016-02-16
    Sponsor Name:GRUPO ESPAÑOL MULTICISPLINAR DE MELANOMA
    Full Title: Phase II multicente, non randomized, open label trial of nivolumab in combination with ipilimumab in subjects with previously untreated metastatic uveal melanoma.
    Medical condition: Metastatic uveal melanoma non suitable for radical resection.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002686-19 Sponsor Protocol Number: 2018-HJEPharma-001 Start Date*: 2018-11-07
    Sponsor Name:Department of Cardiology, Copenhagen University Hospital Rigshospitalet
    Full Title: Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response after Out-of-Hospital Cardiac Arrest
    Medical condition: We investigate the efficacy of commercially available interleukin-6 receptor antibody 'RoActemra' for reducing the systemic inflammatory response in patients having been resuscitated after out-of-h...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007515 Cardiac arrest PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-004318-25 Sponsor Protocol Number: NL63681.029.18 Start Date*: 2019-04-16
    Sponsor Name:VU University Medical Center
    Full Title: Early high-dose vitamin C in post-cardiac arrest syndrome.
    Medical condition: Patients admitted to the Intensive Care after out-of-hospital cardiac arrest with return of spontaneous circulation, ventricular fibrillation or ventricular tachycardia as first registered cardiac ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10078202 Post cardiac arrest syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006562-20 Sponsor Protocol Number: JAKIPRA Start Date*: 2022-10-26
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: JAK Inhibition in PReclinical Arthritis
    Medical condition: Preclinical Phase of rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001546-18 Sponsor Protocol Number: GETNE-T1913 Start Date*: 2019-08-19
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
    Full Title: A phase II study of Platinum-doublet chemotherapy in combination with nivolumab as first-line treatment, in subjects with unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (N...
    Medical condition: Unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or of unknown (UK) origin.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071542 Neuroendocrine carcinoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-001620-33 Sponsor Protocol Number: APHP200033 Start Date*: 2021-01-13
    Sponsor Name:ASSISTANCE-PUBLIQUE HOPITAUX DE PARIS (AP-HP)
    Full Title: HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome
    Medical condition: Adult cardiac arrest patients with sustained ROSC and hemodynamic failure due to post-resuscitation syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005607-24 Sponsor Protocol Number: 8-79-52030-326 Start Date*: 2015-11-30
    Sponsor Name:Ipsen Innovation
    Full Title: Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having ...
    Medical condition: well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) DK (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001489-17 Sponsor Protocol Number: SIOPENRNET003 Start Date*: 2006-11-17
    Sponsor Name:St. Anna Kinderkrebsforschung e.V.
    Full Title: High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)
    Medical condition: High Risk Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) ES (Restarted) GB (GB - no longer in EU/EEA) BE (Completed) DK (Restarted) IT (Completed) IE (Completed) HU (Completed) FI (Completed) SI (Completed) PL (Completed) GR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 19:54:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA